WallStSmart

HCA Holdings Inc (HCA)vsLam Research Corp (LRCX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Holdings Inc generates 268% more annual revenue ($75.60B vs $20.56B). LRCX leads profitability with a 30.2% profit margin vs 9.0%. HCA appears more attractively valued with a PEG of 1.35. LRCX earns a higher WallStSmart Score of 74/100 (B).

HCA

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

LRCX

Strong Buy

74

out of 100

Grade: B

Growth: 7.3Profit: 10.0Value: 8.0Quality: 7.8
Piotroski: 6/9Altman Z: 4.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCAUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$1326.31

Current Price

$484.02

$842.29 discount

UndervaluedFair: $1326.31Overvalued
LRCXFair Value (-2.4%)

Margin of Safety

-2.4%

Fair Value

$227.92

Current Price

$233.45

$5.53 premium

UndervaluedFair: $227.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-8.3310/10

Conservative balance sheet, low leverage

Market CapQuality
$108.62B9/10

Large-cap with strong market position

P/E RatioValuation
17.1x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
44.5%8/10

Earnings expanding 44.5% YoY

LRCX6 strengths · Avg: 9.7/10
Market CapQuality
$299.99B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
65.6%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
30.2%10/10

Keeps 30 of every $100 in revenue as profit

Operating MarginProfitability
33.9%10/10

Strong operational efficiency at 33.9%

Altman Z-ScoreHealth
4.6510/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

Areas to Watch

HCA1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

LRCX3 concerns · Avg: 2.7/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

P/E RatioValuation
49.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.8x2/10

Trading at 28.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : LRCX

The strongest argument for LRCX centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 30.2% and operating margin at 33.9%. Revenue growth of 22.1% demonstrates continued momentum.

Bear Case : HCA

The primary concerns for HCA are Altman Z-Score.

Bear Case : LRCX

The primary concerns for LRCX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 49.0x leaves little room for execution misses.

Key Dynamics to Monitor

HCA profiles as a value stock while LRCX is a growth play — different risk/reward profiles.

LRCX carries more volatility with a beta of 1.79 — expect wider price swings.

LRCX is growing revenue faster at 22.1% — sustainability is the question.

LRCX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

LRCX scores higher overall (74/100 vs 69/100), backed by strong 30.2% margins and 22.1% revenue growth. HCA offers better value entry with a 59.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Lam Research Corp

TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA

Lam Research Corporation is an American corporation that engages in the design, manufacture, marketing, and service of semiconductor processing equipment used in the fabrication of integrated circuits. Its products are used primarily in front-end wafer processing, which involves the steps that create the active components of semiconductor devices (transistors, capacitors) and their wiring (interconnects). The company also builds equipment for back-end wafer-level packaging (WLP), and for related manufacturing markets such as for microelectromechanical systems (MEMS). The company is headquartered in Fremont, California, in the Silicon Valley.

Want to dig deeper into these stocks?